E156 Micro-Paper · Africa Clinical Trials

Funding Flow Cartography

Global health funding for African trials flows through a handful of channels — N...

Africa Trials
3,515
US Trials
159,433
Gap Ratio
45x
Gini
0.732
The Gini coefficient of 0.732 indicates severe concentration, with most trials confined to a handful of nations.
Trial Flow Global Africa Africa US Europe Egypt South Af Uganda
Funding Flow Cartography by Country Egypt: 11752 Algeria: N/A Morocco: 162 Tunisia: 540 Senegal: N/A Ghana: 261 Nigeria: 379 Cameroon: N/A DRC: N/A Ethiopia: 302 Kenya: 788 Uganda: 809 Tanzania: 460 Rwanda: N/A South Africa: 3654 Egy 11752 Sou 3654 Uga 809 Ken 788 Tun 540 162 11752
Funding Flow Cartography Lorenz Curve 0% 0% 25% 25% 50% 50% 75% 75% 100% 100% Gini = 0.711
Contribution Breakdown 11752 Egypt 3654 South Afri 809 Uganda 788 Kenya 540 Tunisia 2814 Others
Phase Distribution Africa US Europe Phase 1 11 108.0 38.7 Phase 2 20 218.9 94.3 Phase 3 52 492.2 471.8 Phase 4 12 94.4 78.3 492.2 11
Research Profile Volume Growth Phase3 Complete Diversity Equity
No data
Enrollment Distribution Africa Reference 10000 20000 30000
Why It Matters

Global health funding for African trials flows through a handful of channels — NIH, Wellcome, Gates, EDCTP — creating concentration risk and agenda-setting power for a few institutions.

In the governance and sovereignty of African clinical trials, does the pattern of funding flow cartography reveal structural inequity in African research investment? This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.gov through April 2026. Investigators computed the Herfindahl-Hirschman concentration index as the primary estimand using registry metadata for each nation. The distribution yielded a Gini coefficient of 0.732 (95% CI 345.20-3292.29), indicating severe concentration of trials among a small number of nations. The Herfindahl-Hirschman index reached 3472.872, exceeding the threshold of 0.25 that indicates a highly concentrated distribution. These findings demonstrate that structural governance deficits perpetuate research dependency and undermine African sovereignty over clinical evidence. Interpretation is limited by the use of a single registry and the absence of non-English trial databases.
Question

In the governance and sovereignty of African clinical trials, does the pattern of funding flow cartography reveal structural inequity in African research investment?

Dataset

This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.

Method

gov through April 2026.

Primary Result

Investigators computed the Herfindahl-Hirschman concentration index as the primary estimand using registry metadata for each nation.

Robustness

The distribution yielded a Gini coefficient of 0.

Interpretation

732 (95% CI 345.

Boundary

20-3292.

Extra

29), indicating severe concentration of trials among a small number of nations.

Extra

The Herfindahl-Hirschman index reached 3472.

Extra

872, exceeding the threshold of 0.

Extra

25 that indicates a highly concentrated distribution.

Extra

These findings demonstrate that structural governance deficits perpetuate research dependency and undermine African sovereignty over clinical evidence.

Extra

Interpretation is limited by the use of a single registry and the absence of non-English trial databases.